Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) Clear all
Recruiting Phase 3 Interventional

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

NCT06928272
View directory record Official record
Conditions
Long COVID
Interventions
Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
Douglas D. Fraser
Other
Eligibility
18 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Withdrawn Phase 2 Interventional

A Study of Combination Therapies to Treat COVID-19 Infection

NCT04459702
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection, Coronavirus Infection, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, Coronavirus-19, SARS-CoV 2, SARS Pneumonia
Interventions
hydroxychloroquine, Azithromycin, Ritonavir, Lopinavir
Drug
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

suPAR Michigan M2C2 Heterogeneity Validation Cohort Study

NCT07466524
View directory record Official record
Conditions
COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
Interventions
suPARnostic® TurbiLatex Assay on Roche cobas c501
Diagnostic Test
Lead sponsor
ViroGates A/S
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

NCT04587323
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC

NCT05514691
View directory record Official record
Conditions
COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic, SARS-CoV-2 Infection
Interventions
iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp")
Diagnostic Test
Lead sponsor
bioLytical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Elkridge, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04847596
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Covid-19 vaccine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

NCT04644120
View directory record Official record
Conditions
CoronaVirus Disease-2019 (COVID-19)
Interventions
ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)

NCT04487886
View directory record Official record
Conditions
COVID-19
Interventions
Duvelisib, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

NCT05172024
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
15,172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional

Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID

NCT06172803
View directory record Official record
Conditions
Long Covid19, Exercise Intolerance, Riboflavin-Responsive
Interventions
Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise, Light Stretching/Breathing Exercises
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)

NCT05131594
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional Results available

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NCT06191393
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions
Aptitude Medical Systems Metrix COVID/Flu Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
2 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 21, 2026, 9:45 AM EDT
Completed No phase listed Observational

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

NCT04401449
View directory record Official record
Conditions
Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional

A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID

NCT06586398
View directory record Official record
Conditions
Long Covid-19, PASC Post Acute Sequelae of COVID 19, Brain Fog, Fatigue
Interventions
rTMS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

NCT04346615
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Zavegepant (BHV-3500), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
S-217622, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
2,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Guntersville, Alabama • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

NCT04565249
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, SARS-CoV-2
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic

NCT04459455
View directory record Official record
Conditions
Anxiety
Interventions
Contain COVID Anxiety SSI, Remain COVID Free SSI
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 9:45 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

NCT05870839
View directory record Official record
Conditions
SARS-CoV, SARS-CoV-2
Interventions
VXCO-100
Biological
Lead sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 9:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Bioaerosol Sampling Device (BSD) Clinical Study

NCT06047067
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Cantor BioConnect, Inc.
Network
Eligibility
5 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
South Gate, California • Hollywood, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 9:45 AM EDT